Importantly, even if these tumours had never received any treatment in vivo, we measured reduced cell rounding, p-MLC2 levels and ki-67 positive cells in ROCKi pre-treated tumours (Fig. 5b–d). This evidence concerns the gene MYL12B and neoplasm.